Amivas Inc.
Carole Doucette-Ferraro is an experienced professional in the pharmaceutical industry, currently serving as Vice President of Sales and Operations at Amivas Inc., a joint venture focused on developing therapeutics for life-threatening diseases, since July 2022. Doucette-Ferraro also operates as a self-employed pharmaceutical consultant, specializing in identifying market opportunities and executing product launch initiatives for pharmaceutical companies in Canada since November 2019. Prior roles include Vice President of Sales & Marketing at Juno Pharmaceuticals Canada, National Sales Director at Hikma Pharmaceuticals, and various leadership positions at Apotex Inc. spanning from October 1991 to July 2018. Doucette-Ferraro’s educational background includes a Bachelor of Science (Honours) from the University of Toronto and ongoing studies for a Master of Science in Marketing from Edinburgh Business School at Heriot-Watt University.
This person is not in any teams
This person is not in any offices
Amivas Inc.
AMIVAS is a US, Australian, and European joint venture focused on the development and commercialization of therapeutics for the treatment of life-threatening diseases with offices in the US, Australia and Ireland. AMIVAS manufactures in North America and our partners in Canada, USA and Europe package and supply our product to hospitals and patients in need. AMIVAS’ vision was formed in response to the urgent need for a US and Europe- based firm to assume responsibility for the manufacture and distribution of Artesunate, for the treatment of severe malaria after quinidine gluconate was discontinued in 2019. With the US Food and Drug Administration (FDA) approval of its first commercial product on May 26, 2020, AMIVAS is proud to join the global effort to fight and eradicate malaria.